item management s discussion and analysis of financial condition and results of operations 
liquidity and capital resources since inception  the company has financed its working capital requirements primarily through private and public sales of its debt and equity securities  income earned on the investment of the proceeds from the sale of such securities  and revenues from product sales 
in august  the company issued and sold in a private placement offering  an aggregate principal amount of  of convertible debentures due july   and received net proceeds  after offering costs  of  see note to the financial statements 
on december   the company had available working capital of approximately  consisting principally of cash  cash equivalents  and marketable securities 
it increased approximately  or  from december   which was attributable to the convertible debenture offering  offset by cash used in operations 
in march  the company issued and sold in a private placement offering shares of series a convertible preferred stock at  per share  for total gross proceeds of  the company received net proceeds  after offering costs  of approximately  the proceeds from the sale of the preferred stock increased the company s working capital on a pro forma basis to approximately  as of december  see note of the financial statements 
in august  the company entered into a two year research and development agreement with the rockefeller university 
this agreement has been extended through july under the terms of the contract extension  the company is committed to pay rockefeller university  annually 
during the year ended december   capital expenditures totalled approximately  primarily for equipment and leasehold improvements to expand its process development and manufacturing capabilities 
in the fourth quarter of  the us fda approved the company s request to recover costs of providing its synovir drug to aids patients eligible for entry into the company s expanded trial for cachexia  a severe wasting condition 
the cost per patient for a twelve week supply will be at present  the company cannot estimate the impact that the potential recovery of costs will have on the company s operations 
the recovery of such costs for was immaterial 
the company believes that its current resources and income derived from investments plus revenues from chiral product sales  research contracts  and estimated recoveries under the fda approved synovir cost recovery program will be sufficient to meet the company s capital requirements for the balance of and however  to assure funding for the company s future operations the company is likely to seek additional capital resources 
these may include the sale of additional securities under appropriate market conditions  alliances or other partnership agreements with entities interested in and possessing resources to support the company s immunotherapeutic or chiral programs  or other business transactions which would generate sufficient resources to assure continuation of the company s operations and research programs in the long term 
however  no assurances can be given that the company will be successful in raising such additional capital or entering into a business alliance 
further  there can be no assurance  assuming the company successfully raises additional funds or enters into a business alliance  that the company will achieve profitability or positive cash flow 
as of december   the company had for federal income tax purposes a net operating loss carryforward of approximately  if not utilized to offset future taxable income  such loss carryforward will expire between and certain events  including any sales by the company of shares of its stock and or transfers of a substantial number of shares of common stock by the current stockholders  may restrict the ability of the company to utilize its net operating loss carryforward 
results of operations year ended december  v 
year ended december  revenues for the year ended december  were approximately  which was a decrease of approximately  or  over the comparable period in chiral intermediate revenues decreased  to  or  for as compared to the decrease in chiral intermediate revenues was due primarily to the sporadic nature of orders from the company s small customer base 
chiral research contract revenues for were  which was an increase of  or  over the increase in research contract revenues was due to the company entering into research contracts for new compounds and for expanding development of existing compounds 
revenue backlog at december  for chiral intermediates and research contracts amounted to  the company had no backlog at december  the company is negotiating with new and existing customers for additional chiral intermediate and research contract orders  however  there is no assurance that these efforts will be successful 
investment income decreased  or  to  in as compared to due to the decrease in funds available for investment during the first half of for  costs of goods sold decreased  or  to  which includes certain fixed manufacturing costs as compared to  due to the low volume of chiral intermediate revenues 
research and development expenses for increased  or  to  as compared to the increase in research and development expenses was due primarily to an increase in the rockefeller university program and clinical trial expenses for the immunotherapeutic program 
these increased expenses were partially offset by decreases in personnel and related expenses for the chiral research group 
selling  general  and administrative expenses decreased  or  to  in as compared to  due to generally lower spending across most expense categories  partially offset by amortization of debt offering costs 
interest expense for was  which related to the debentures issued in july  the net loss for the year ended december  was approximately  an increase of approximately  or  over net loss for the year ended december  included the operating loss of the company s discontinued biotreatment operations of  loss from continuing operations during increased  due primarily to lower chiral intermediates revenues and higher spending for the immunotherapeutic program 
year ended december  v 
year ended december  revenues for the year ended december  were approximately  which was at approximately the same level as compared to chemical intermediates revenue consisting of higher volume sales of chiral products to existing customers increased  or  to  in as compared to chiral research contract revenues for was  which was an increase of  or  over the comparable period in this increase in contract revenues was due to the company entering into research contracts for new compounds with new customers 
investment income decreased approximately  or  to approximately  in as compared to  due to the decrease in funds available for investment 
for the year ended december   cost of goods sold as a percentage of chemical intermediates revenue was as compared to for the comparable period 
the lower cost of goods sold percentage in was due to improved productivity and the volume of products internally manufactured by the company as compared to when a significant volume of products were produced by outside manufacturers 
in the comparative period for  no outside manufacturers were used and all of the company s product revenues were derived from products manufactured by celgene 
research and development expenses for the year ended december  increased  or  to  as compared to the same period in  due to clinical trial expenses for the immunotherapeutic program and  to a lesser extent  to higher personnel and related expenses 
selling  general and administrative expenses for the year ended december  decreased  or to  as compared to primarily due to no incentive bonus expense partially offset by increase personnel and facilities expenses 
net loss for the year ended december  was approximately  which was at the same approximate level as compared to loss from continuing operations increased  or  to  in over the comparable period 
the operating loss of the discontinued operation decreased  to  primarily due to cessation of the company s biotreatment operations during the second quarter of other matters in march  the financial accounting standards board fasb issued statement of financial accounting standards sfas no 
 accounting for the impairment of long lived assets and for long lived assets to be disposed of  which will become effective on january  sfas no 
establishes accounting standards for the impairment of long lived assets  certain identifiable intangibles and goodwill related to those assets to be held and used and for long lived assets and certain identifiable intangibles to be disposed 
adoption of sfas no 
is not expected to have a material impact on the company s consolidated financial position and operating results  nor will it affect the company s cash flows 
in october  the fasb issued sfas no 
 accounting for stock based compensation 
this statement establishes an alternative method of accounting for stock based compensation awarded to employees such as stock options granted by the company to employees 
the standard provides for the recognition of compensation expense based on the fair value of the stock based award  but allows companies to continue to measure compensation cost in accordance with accounting principles board opinion apb no 
 accounting for stock issued to employees 
companies electing to retain this method must make pro forma disclosures of net income and earnings per share as if the fair value based method had been applied 
the company plans to continue to use apb no 
 which does not require the company to record compensation expense for the stock options it awards to employees 
restricted stock awards for which the company presently accrues compensation would continue to be accounted for in that manner 
with respect to fiscal  the company will disclose the pro forma effect of the fair value method on and net income and earnings per share 

